News & Updates

VTE incidence in COVID-19 patients in Sg ICUs lower than expected

19 Mar 2021 by

A lower than expected incidence of venous thromboembolism (VTE) among ICU*-admitted patients with COVID-19, as shown in a retrospective observational study from Singapore, suggests the need to rethink thromboprophylaxis strategies in this setting.

VTE incidence in COVID-19 patients in Sg ICUs lower than expected

19 Mar 2021

Vitamin D deficiency linked to worse lung function in men

19 Mar 2021

Even in apparently healthy men, vitamin D deficiency may aggravate the risk of worsening lung function, reports a recent Korea study.

Vitamin D deficiency linked to worse lung function in men

19 Mar 2021

Dupilumab cuts exacerbations in difficult-to-treat type 2 asthma

19 Mar 2021 by

Dupilumab effectively prevents severe asthma exacerbations and improves lung function in patients with difficult-to-treat type 2 asthma, according to a post hoc analysis of the LIBERTY ASTHMA QUEST study presented at AAAAI 2021.

Dupilumab cuts exacerbations in difficult-to-treat type 2 asthma

19 Mar 2021

Benralizumab may help reduce OCS reliance in asthma

18 Mar 2021 by

Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.

Benralizumab may help reduce OCS reliance in asthma

18 Mar 2021

Bamlanivimab continues to BLAZE through the COVID-19 gloom

18 Mar 2021 by

Two phase III BLAZE* trials presented at CROI 2021 highlight the benefit of bamlanivimab, a potent neutralizing monoclonal antibody (nMAb), for the treatment and prevention of COVID-19.

Bamlanivimab continues to BLAZE through the COVID-19 gloom

18 Mar 2021

Four repurposed antivirals show no benefit for COVID-19 mortality

17 Mar 2021 by

The four original drugs tested in the WHO Solidarity trial – remdesivir, lopinavir, hydroxychloroquine, and interferon beta-1a – have shown no benefit on mortality, initiation of ventilation, or duration of hospitalization in patients hospitalized with COVID-19, interim trial results show.

Four repurposed antivirals show no benefit for COVID-19 mortality

17 Mar 2021

Safe to continue common BP meds in hospitalized COVID-19 patients: global trial data

16 Mar 2021 by

Continuing RAS* inhibitors — a group of commonly used antihypertensive medications — was safe in patients hospitalized with COVID-19, without worsening clinical outcomes, the international REPLACE COVID randomized trial has shown.

Safe to continue common BP meds in hospitalized COVID-19 patients: global trial data

16 Mar 2021

Anaphylaxis after first Pfizer-BioNTech COVID-19 vaccine dose rare

16 Mar 2021 by

Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.